To validate and compare the functional consequences of HIF1α and HIF2α suppression in vivo, we utilized two AML patient‐derived xenograft (PDX) models from leukemia samples collected at diagnosis (Toffalori et al, 2019). The gene discussed is HIF1A; the disease is acute myeloid leukemia.